RVPH Stock Overview
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Reviva Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.90 |
52 Week High | US$9.25 |
52 Week Low | US$2.67 |
Beta | -0.023 |
1 Month Change | -10.34% |
3 Month Change | -22.16% |
1 Year Change | -16.31% |
3 Year Change | -32.06% |
5 Year Change | -61.39% |
Change since IPO | -59.84% |
Recent News & Updates
Recent updates
Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely
Aug 24We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate
Dec 28Reviva Pharmaceuticals drops 9% on $8.5M private placement
Sep 06We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate
Aug 24Reviva Pharmaceuticals Q2 GAAP loss per share widens
Aug 15Reviva reports positive brilaroxazine results in Aacute Schizophrenia
Apr 26Shareholder Returns
RVPH | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 39.3% | 1.2% | 0.4% |
1Y | -16.3% | 25.8% | 28.8% |
Return vs Industry: RVPH underperformed the US Pharmaceuticals industry which returned 23.9% over the past year.
Return vs Market: RVPH underperformed the US Market which returned 29.5% over the past year.
Price Volatility
RVPH volatility | |
---|---|
RVPH Average Weekly Movement | 11.9% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RVPH's share price has been volatile over the past 3 months.
Volatility Over Time: RVPH's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 10 | Laxminarayan Bhat | https://www.revivapharma.com |
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company’s lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease, Parkinson’s disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity.
Reviva Pharmaceuticals Holdings, Inc. Fundamentals Summary
RVPH fundamental statistics | |
---|---|
Market cap | US$108.88m |
Earnings (TTM) | -US$37.65m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs RVPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RVPH income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$37.65m |
Earnings | -US$37.65m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.35 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -2.6% |
How did RVPH perform over the long term?
See historical performance and comparison